ADP-ribosylation from molecular mechanisms to therapeutic implications
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
ADP-ribosylation is a ubiquitous modification of biomolecules, including proteins and nucleic acids, that regulates various cellular functions in all kingdoms of life. The recent emergence of new technologies to study ADP-ribosylation has reshaped our understanding of the molecular mechanisms that govern the establishment, removal, and recognition of this modification, as well as its impact on cellular and organismal function. These advances have also revealed the intricate involvement of ADP-ribosylation in human physiology and pathology and the enormous potential that their manipulation holds for therapy. In this review, we present the state-of-the-art findings covering the work in structural biology, biochemistry, cell biology, and clinical aspects of ADP-ribosylation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 3×
“3,4 With a view to reducing toxic side effects of PARPi that seem to be caused primarily by PARP2 inhibition, more selective PARP1 inhibitors such as AZD5305 have been developed 177 and entered clinical trials.”
BackgroundSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Haigis, M. C., Mostoslavsky, R., Haigis, K. M., Fahie, K., Christodoulou, D. C., Murphy, A. J., Valenzuela, D. M., Yancopoulos, G. D., Karow, M., Blander, G., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.057 · Cited by 1,162
SIRT6 Promotes DNA Repair Under Stress by Activating PARP1
Mao, Z., Hine, C., Tian, X., Van Meter, M., Au, M., Vaidya, A., Seluanov, A., & Gorbunova, V. (2011) · Science · doi:10.1126/science.1202723 · Cited by 867
PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes
Gupte, R., Liu, Z., & Kraus, W. L. (2017) · Genes & Development · doi:10.1101/gad.291518.116 · Cited by 681 · cited 1×
“5,76,104,105 Below, some of them are covered, grouped by the specific associated ADP-ribosylation writers with a focus on human biology.”
BackgroundPoly(ADP-ribose)–Dependent Regulation of DNA Repair by the Chromatin Remodeling Enzyme ALC1
Ahel, D., Hořejší, Z., Wiechens, N., Polo, S. E., Garcia-Wilson, E., Ahel, I., Flynn, H., Skehel, M., West, S. C., Jackson, S. P., et al. (2009) · Science · doi:10.1126/science.1177321 · Cited by 588
Self-citationHigh speed of fork progression induces DNA replication stress and genomic instability
Maya-Mendoza, A., Moudry, P., Merchut-Maya, J. M., Lee, M., Strauss, R., & Bartek, J. (2018) · Nature · doi:10.1038/s41586-018-0261-5 · Cited by 514 · cited 1×
“116 The exact mechanism underlying PARP1’s impact on replication forks remains unclear.”
BackgroundPoly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson’s disease
Kam, T.-I., Mao, X., Park, H., Chou, S.-C., Karuppagounder, S. S., Umanah, G. E., Yun, S. P., Brahmachari, S., Panicker, N., Chen, R., et al. (2018) · Science · doi:10.1126/science.aat8407 · Cited by 476
Serine ADP-ribosylation depends on HPF1
Bonfiglio, J. J., Fontana, P., Zhang, Q., Colby, T., Gibbs-Seymour, I., Atanassov, I., Bartlett, E., Zaja, R., Ahel, I., & Matic, I. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.01.003 · Cited by 352 · cited 2×
“56,57 These complexes have a compound active site with two catalytic glutamates: one (for oxocarbenium stabilization) provided by the PARP enzyme and the other (likely for serine deprotonation) provided by HPF1 58 (Figure 3B).”
BackgroundSelf-citationCambronne, X. A., & Kraus, W. L. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.05.010 · Cited by 137
Yang, C.-S., Jividen, K., Kamata, T., Dworak, N., Oostdyk, L., Remlein, B., Pourfarjam, Y., Kim, I.-K., Du, K.-P., Abbas, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23055-6 · Cited by 44
Cited by
Identification of RNF114 as ADPr-Ub reader through non-hydrolysable ubiquitinated ADP-ribose
Kloet, M. S., Chatrin, C., Mukhopadhyay, R., van Tol, B. D. M., Smith, R., Rotman, S. A., Tjokrodirijo, R. T. N., Zhu, K., Gorelik, A., Maginn, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61111-7 · Cited by 30
Self-citationDeazaguanylation is a nucleobase-protein conjugation required for type IV CBASS immunity
Wassarman, D. R., Pfaff, P., Paulo, J. A., Gygi, S. P., Shokat, K. M., & Kranzusch, P. J. (2025) · Science · doi:10.1126/science.adx6053 · Cited by 9
Metadata
- Authors
- Suskiewicz, M. J., Prokhorova, E., Rack, J. G. M., & Ahel, I.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2023-10
- Volume
- 186
- Issue
- 21
- Pages
- 4475-4495
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W4387566852
- Cited by
- 189
- References
- 11
- FWCI
- 14.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.